Related Experiment Video
Updated: Aug 9, 2026
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Oral CCR5 inhibitors: will they make it through?
Priscilla Biswas1, Silvia Nozza, Gabriella Scarlatti
1San Raffaele Scientific Institute, Laboratory of Clinical Immunology, Clinic of Infectious Diseases, Via Stamira d'Ancona 20, 20127 Milan, Italy. biswas.priscilla@hsr.it
Expert Opinion on Investigational Drugs
|April 26, 2006
Summary
A new class of HIV drugs, entry inhibitors, targets the CCR5 co-receptor. Blocking CCR5 shows promise for treating HIV-1 infection, especially since CCR5 variants are common in healthy individuals.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Human Immunodeficiency Virus (HIV) entry involves interactions with cellular receptors.
- The primary receptor is CD4, with co-receptors CCR5 or CXCR4.
- Most HIV variants utilize CCR5 for cellular entry.
Purpose of the Study:
- To introduce novel antiretroviral entry inhibitors for HIV therapy.
- To highlight CCR5 as a therapeutic target for HIV-1 infection.
- To discuss the development of CCR5 antagonists.
Main Methods:
- Review of recent advancements in HIV entry inhibition.
- Analysis of the role of CCR5 in HIV pathogenesis.
- Discussion of small-molecule CCR5 antagonists.
Main Results:
- Entry inhibitors represent a novel class of antiretrovirals.
- CCR5 is a key co-receptor for the majority of HIV strains.
- Individuals with CCR5 gene mutations remain healthy, suggesting CCR5's role in infection.
Conclusions:
- CCR5 is a viable and attractive target for HIV-1 treatment.
- Development of orally bioavailable CCR5 antagonists is promising.
- Further research into CCR5 antagonism is warranted for HIV therapy.
More Related Videos
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...